Develops enzyme replacement therapies for rare genetic diseases.
Jun 2026Revenue $80.6M/yrExpenses $57.3M/yr
No trend
Figures by year
Is Protalix BioTherapeutics profitable?
Yes. In the 12 months to Jun 2026, revenue was $80.6M and expenses $57.3M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $52.7M | $58.2M | −$5.50M |
| Dec 2024 | $53.4M | $49.5M | $3.92M |
| Dec 2023 | $65.5M | $55.0M | $10.5M |
| Dec 2022 | $47.6M | $60.7M | −$13.0M |
| Dec 2021 | $38.4M | $58.8M | −$20.5M |
| Dec 2020 | $62.9M | $60.2M | $2.71M |
| Dec 2019 | $54.7M | $65.4M | −$10.7M |
| Dec 2018 | $34.2M | $53.5M | −$19.3M |
| Dec 2017 | $21.1M | $55.6M | −$34.5M |
| Dec 2016 | $9.20M | $42.4M | −$33.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.